BioSpace News Archive

V-Wave Inc., a privately held medical device company, announced primary results from the RELIEVE-HF pivotal trial of its Ventura® Interatrial Shunt.

Ocular Therapeutix, Inc. announced positive Phase 2 data for PAXTRAVA in patients with open-angle glaucoma or ocular hypertension The data are being presented by Mark Gallardo, MD during the 2024 American Society of Cataract and Refractive Surgery Annual Meeting.

OASIS® Medical Inc., manufacturer and distributor of disposable surgical solutions and dry eye solution brands Oasis TEARS® and SOFT PLUG® punctal plugs launch the SOFT PLUG® Extended Duration 180-T Tapered Plug at ASCRS booth 2675 in Boston.

Bristol Myers Squibb announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT in adults with schizophrenia.

Bristol Myers Squibb announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT in adults with schizophrenia.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the presentation of eight studies from its LAI schizophrenia research program, including data evaluating UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults.

egnite, Inc., a leading digital health company for cardiovascular care, and JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo.

Amarin Corporation plc highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® on reducing MACE in patients with baseline high or low Lipoprotein [Lp] levels, as well as reducing the risk of cardiovascular events in patients irrespective of baseline LDL-C level.

Novartis announced new data demonstrating the early addition of twice-yearly* Leqvio® to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol in patients with atherosclerotic cardiovascular disease, including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone.